A Phase 2 interventional study of ONO-1110 and Placebo in Hunner Type Interstitial Cystitis, sponsored by Ono Pharmaceutical Co., Ltd.. Completed at 20 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Hunner Type Interstitial Cystitis
236 studies on the registry are indexed under Cystitis, Interstitial; 35 are open to participants now.
This study's enrollment of 57 is above the median of 51 across 158 interventional studies indexed under Cystitis, Interstitial.
Browse Cystitis, Interstitial studies →Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ONO-1110 tablets once a day
Drug: ONO-1110
Placebo tablets once daily
Drug: Placebo
ONO-1110 tablets once a day
Placebo tablets once daily
Change in weekly mean of average pain score from baseline to Week 12 of the treatment period
Time frame: Up to 20 weeks
Adverse events
Time frame: Up to 20 weeks
Change in weekly mean of average pain score from baseline in each week
Time frame: Up to 20 weeks
30%- and 50%-responder rates based on the weekly mean of average pain score
proportions of participants whose weekly mean of average pain score has decreased by 30% and 50% from baseline, respectively
Time frame: Up to 20 weeks
Change in weekly mean of worst pain score from baseline to each week
Time frame: Up to 20 weeks
30%- and 50%-responder rates based on the weekly mean of worst pain score
proportions of participants whose weekly mean of worst pain score has decreased by 30% and 50% from baseline, respectively
Time frame: Up to 20 weeks
Change in Interstitial cystitis symptom index (ICSI) score from baseline
Time frame: Up to 20 weeks
Change in Interstitial cystitis problem index (ICPI) score from baseline
Time frame: Up to 20 weeks
Change in Average frequency of urination per day from baseline
Time frame: Up to 20 weeks
Change in Frequency of nocturnal urination per day from baseline
Time frame: Up to 20 weeks
Change in Mean volume voided per micturition in a day from baseline
Time frame: Up to 20 weeks
Change in Maximum volume voided per micturition in a day from baseline
Time frame: Up to 20 weeks
Change in Number of urgency episodes per day from baseline
Time frame: Up to 20 weeks
Change in Patient Global Impression of Change (PGIC) score from baseline
Time frame: Up to 20 weeks
Change in SF-12v2 score from baseline
Time frame: Up to 20 weeks
Change in Hospital Anxiety and Depression Scale (HADS) score from baseline
Time frame: Up to 20 weeks
Plasma ONO-1110 concentrations
Time frame: Up to 20 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2025 to primary completion in Jun 2026, 14 months.
Of 19 phase 2 interventional studies under Cystitis, Interstitial, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 34. This study's 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ONO-1110
Ono Pharmaceutical Co., Ltd. →